Urologic Oncology-Seminars and Original Investigations

Papers
(The H4-Index of Urologic Oncology-Seminars and Original Investigations is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Urinary biomarkers in bladder cancer: A review of the current landscape and future directions117
Papillary renal cell carcinoma: Review45
Investigating the association between the urinary microbiome and bladder cancer: An exploratory study41
Non-muscle-invasive bladder cancer: An overview of potential new treatment options38
Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy37
Phase I trial of docetaxel plus lutetium-177-labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 (177Lu‐J591) for metastatic castration‐resistant prostate cancer30
Bacillus Calmette-Guerin (BCG): Its fight against pathogens and cancer30
Androgen receptor inhibitor treatments: Cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer28
Differential efficacy of ablation therapy versus partial nephrectomy between clinical T1a and T1b renal tumors: A systematic review and meta-analysis27
Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients26
Head-to-head comparison of all the prognostic models recommended by the European Association of Urology Guidelines to predict oncologic outcomes in patients with renal cell carcinoma26
Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis25
Development of robust artificial neural networks for prediction of 5-year survival in bladder cancer25
Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer25
Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer25
Oncological outcomes of salvage radical prostatectomy for recurrent prostate cancer in the contemporary era: A multicenter retrospective study25
PI-RADS 3 lesions: Does the association of the lesion volume with the prostate-specific antigen density matter in the diagnosis of clinically significant prostate cancer?24
Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer23
Trends in the use of active surveillance and treatments in Medicare beneficiaries diagnosed with localized prostate cancer23
A national cross-sectional survey of financial toxicity among bladder cancer patients23
Clinical utility of PSAD combined with PI-RADS category for the detection of clinically significant prostate cancer23
Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder23
Repurposing metformin as anticancer drug: Randomized controlled trial in advanced prostate cancer (MANSMED)22
Telemedicine in management of genitourinary malignancies: Patient and physician perspectives22
0.35580897331238